PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Endometriosis: An overview PART 05: Pipeline analysis • Pipeline molecules based on their mechanism PART 06: Key buying criteria for endometriosis drugs PART 07: Market landscape • Market overview • Five forces analysis PART 08: Market segmentation by type of therapy • Hormone therapy • Market size and forecast • Pain medications • Market size and forecast PART 09: Market segmentation by ROA • Oral • Parenteral • Intrauterine systems • Nasal spray PART 10: Geographical segmentation • Global endometriosis drugs market by geography 2015-2020 • Endometriosis drugs market in Americas • Endometriosis drugs market in EMEA • Endometriosis drugs market in APAC PART 11: Market drivers • Recurrence of endometriosis • Increased adoption on OCPs • Ineffective existing therapies leading to high unmet need PART 12: Impact of drivers PART 13: Market challenges • Poor compliance rates leading to high dropouts • Surgeries as primary treatment option • Unavailability of proper diagnostic tools PART 14: Impact of drivers and challenges PART 15: Market trends • Replacement of GnRH agonists by GnRH antagonists • Increased focus on IUDs • Development of novel targets for treatment PART 16: Vendor landscape • Competitive scenario • Key news • Major upcoming vendors PART 17: Key vendor analysis • AbbVie • AstraZeneca • Bayer HealthCare • Pfizer • Other prominent vendors PART 18: Appendix • List of abbreviations PART 19: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Pipeline portfolio: Global endometriosis drugs market Exhibit 03: Segmentation of pipeline molecules in different stages of development Exhibit 04: Segmentation of pipeline molecules based on their mechanism of action Exhibit 05: Impact of GnRH antagonists on global endometriosis market Exhibit 06: Competitive assessment of marketed and late-stage pipeline molecules Exhibit 07: Key buying criteria for endometriosis drugs Exhibit 08: Global endometriosis market snapshot: Developed and emerging markets 2015 Exhibit 09: Global endometriosis drugs market 2015-2020 ($ billions) Exhibit 10: Opportunity analysis: Global endometriosis drugs market Exhibit 11: Five forces analysis Exhibit 12: Segmentation of global endometriosis drugs market by type of therapy Exhibit 13: Global endometriosis market segmentation by type of therapy 2015 Exhibit 14: Hormone therapies market for endometriosis 2015-2020 ($ billions) Exhibit 15: Pain medications market for endometriosis 2015-2020 ($ millions) Exhibit 16: Global endometriosis market by type of therapy 2015-2020 Exhibit 17: Global endometriosis drugs market by geography 2015-2020 Exhibit 18: Segmentation of global endometriosis drugs market by geography 2015 and 2020 Exhibit 19: Segmentation of global endometriosis drugs market by geography 2015-2020 ($ millions) Exhibit 20: Global endometriosis market by geography 2015-2020 Exhibit 21: Endometriosis drugs market in Americas 2015-2020 ($ millions) Exhibit 22: Endometriosis prevalence in EMEA Exhibit 23: Endometriosis drugs market in EMEA 2015-2020 ($ millions) Exhibit 24: Endometriosis drugs market in APAC 2015-2020 ($ millions) Exhibit 25: Impact of drivers Exhibit 26: Impact of drivers and challenges Exhibit 27: Market share of top vendors in global endometriosis drugs market 2015 Exhibit 28: Geographical presence of major vendors in global endometriosis market Exhibit 29: Competitive scenario of vendors in global endometriosis market 2015-2020 Exhibit 30: Major upcoming vendors in global endometriosis market Exhibit 31: AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions) Exhibit 32: AbbVie: Geographical segmentation of Lupron by revenue 2015 Exhibit 33: AbbVie: Metrics analysis Exhibit 34: AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions) Exhibit 35: AstraZeneca: Geographic segmentation of Zoladex 2015 Exhibit 36: AstraZeneca: Metrics analysis Exhibit 37: Bayer: YoY revenue and growth rate of Mirena 2013-2015 ($ billions) Exhibit 38: Bayer HealthCare: Metrics analysis Exhibit 39: Pfizer: YoY revenue and growth rate of Depo-Provera 2013-2015 ($ millions) Exhibit 40: Pfizer: Metrics analysis

AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, Endoceutics, Euroscreen, Forendo Pharma, Isifer, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, ObsEva, Orphagen Pharmaceuticals, Philogen, PregLem, Repros Therapeutics, Roivant Sciences, SK Chemicals, Speciality European Pharma, SYNG Pharmaceuticals, Takeda, United Pharmaceuticals, ValiPharma.